[Skip to Content]
Research
Research
Research
Treatment
Treatment
Tobacco Users
Tobacco Users
Businesses
Businesses
Education
Education
Contact Us
Contact the ACT Center

Grants

2013 - 2017 American Heart Association Tobacco Regulation and Addiction Center (A-TRAC)
NHLBI P50 HL120163-01 TCORS
2002 - 2014 Mapping Susceptibility Loci for Nicotine Dependence
NIDA DA-12844
2010 - 2011 A Second Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy, Immunogenicity and Safety of 3'-aminomethylnicotine-P. aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX) as an Aid to Smoking Cessation
Nabi Biopharmaceuticals
2008 - 2010 Influence of Provider Individual Differences on Tobacco Treatment Training Outcomes
Pfizer
2005 - 2009 Tobacco Cessation via Public Health Dental Clinics
NCI R01 CA107442-01A2
2003 - 2007 Tobacco Quitlines: Adjunct to Dental Interventions
NIDA DA-017972-01
2004 - 2005 Clinical Trial DRI5154
Sanofi - Synthelabo

Comparison of the Efficacy and Safety of 3 Oral Doses of SSR591813L, 20 mg, 40 mg, 80 mg twice daily versus Placebo, as an Aid to Smoking Cessation. A US, Multi-Center, Randomized, Double-blind, 4-Arm, Fixed Dose, 7-Week Treatment, PHASE II Trial.

2002 - 2005 Clinical Trial EFC4796
Sanofi - Synthelabo

Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 5 mg / day or 20 mg / day, versus Placebo, as an Aid to Maintenance of Smoking Cessation - A Multiple Country, Randomized, Double-blind, 5 Arm, Placebo-Controlled, Parallel-Group, Fixed Dose, 2-year, Multi-Center, Phase III Trial: 1-Year Treatment, 1-Year Follow-up.

2002 - 2005 Smoking Cessation Research in Primary Care Treatment Centers
GlaxoSmithKline
2002 - 2003 Clinical Trial A3051018
Pfizer

A Forty-Week, Double-Blind, Multicenter, Non-Treatment Study Extension to Study A3051007 Evaluating the Efficacy of Four Dosing Strategies for CP-526,555 (0.5 mg BID, titrated 0.5 mg BID, 1 mg BID and titrated 1 mg BID) in Smoking Cessation.

2001 - 2003 Chewer's Choice
NCI
2001 - 2002 Clinical Trial A3051007
Pfizer

A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety and Efficacy of Four Dosing Strategies for CP-526,555 (0.5 mg BID, titrated 0.5 mg BID, 1 mg BID and titrated 1 mg BID) in Smoking Cessation.

1999 - 2002 Guideline Implementation for Tobacco Study
Veterans Affairs HSR&D

The ACT Center at tThe University of Mississippi Medical Center
The University of Mississippi Medical Center